- Home
- RNG vs AGIO Comparison
RNG vs AGIO Comparison
Compare RNG & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNG
- AGIO
- Stock Information
- Founded
- RNG 1999
- AGIO 2007
- Country
- RNG United States
- AGIO United States
- Employees
- RNG N/A
- AGIO N/A
- Industry
- RNG EDP Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- RNG Technology
- AGIO Health Care
- Exchange
- RNG Nasdaq
- AGIO Nasdaq
- Market Cap
- RNG 3.1B
- AGIO 3.0B
- IPO Year
- RNG 2013
- AGIO 2013
- Fundamental
- Price
- RNG $36.51
- AGIO $56.59
- Analyst Decision
- RNG Buy
- AGIO Buy
- Analyst Count
- RNG 15
- AGIO 7
- Target Price
- RNG $40.73
- AGIO $52.33
- AVG Volume (30 Days)
- RNG 1.3M
- AGIO 737.4K
- Earning Date
- RNG 11-07-2024
- AGIO 10-31-2024
- Dividend Yield
- RNG N/A
- AGIO N/A
- EPS Growth
- RNG N/A
- AGIO N/A
- EPS
- RNG N/A
- AGIO 11.80
- Revenue
- RNG $2,357,154,000.00
- AGIO $32,871,000.00
- Revenue This Year
- RNG $9.88
- AGIO $33.38
- Revenue Next Year
- RNG $7.77
- AGIO $163.06
- P/E Ratio
- RNG N/A
- AGIO $4.70
- Revenue Growth
- RNG 9.33
- AGIO 36.79
- 52 Week Low
- RNG $26.98
- AGIO $20.96
- 52 Week High
- RNG $40.98
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- RNG 48.23
- AGIO 62.15
- Support Level
- RNG $34.13
- AGIO $52.09
- Resistance Level
- RNG $36.04
- AGIO $62.58
- Average True Range (ATR)
- RNG 1.60
- AGIO 2.85
- MACD
- RNG -0.40
- AGIO -0.06
- Stochastic Oscillator
- RNG 10.66
- AGIO 63.58
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.